Open: 1.54 Close: 1.47 Change: -0.07

Today's Summary

bioxcel therapeutics completes market opportunity assessment and advances commercialization plans for igalmi® in the at-home setting. Bioxcel Therapeutics, Inc. will build on these insights as we develop and finalize a comprehensive launch plan. bioxcell Therapeutics is under investigation for the acute treatment of agitation associated with Alzheimers dementia.BioXcel Therapeutics an operating loss of $15.9 million and a net loss of $19.2 million for the second quarter of 2025**. IGALMI ® is a registered trademark of BioXcell Therapeutics, Inc.